COMMUNIQUÉS West-GlobeNewswire

Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 ($55,000 CAD based on current exchange rate) research grant to advance microbiota research in human health & disease
23/06/2026
MONTREAL, June 23, 2026 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to supporting scientific projects that explore the microbiome, is inviting grant [...]
GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités
23/06/2026
Le médicament expérimental GNS561 a démontré un profil de sécurité et de tolérabilité favorable dans une étude de Phase 1b évaluant son potentiel en combinaison avec un inhibiteur de MEK (MEKi) Étude menée dans une [...]
Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs
23/06/2026
Data presented at the American Transplant Congress 2026 reports transvenous phrenic nerve stimulation reduced lung collapse and significantly increased availability of lungs that meet transplant criteria versus [...]
Premier Health of America Obtains Creditor Protection Under The CCAA-Operations to Continue Without Interruption
23/06/2026
MONTREAL, June 23, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, further to its news release issued this morning and the hearing of the motion [...]
RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
23/06/2026
MIAMI, June 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support
23/06/2026
New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- Zealthy announced today the launch of its enhanced virtual weight-loss care platform, designed to simplify access to provider-guided obesity treatment through integrated [...]
RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview
23/06/2026
New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx , a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing [...]
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06/2026
Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high - [...]
Applied Biologics Announces Submission of Abstract of Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of The Campx Trial to SAWC Fall 2026
23/06/2026
SCOTTSDALE, Ariz, June 23, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Premier Health of America Announces CCAA Proceedings
23/06/2026
MONTREAL, June 23, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” , or the “Company” ) announces proceedings under the Companies’ Creditors Arrangement Act (Canada) (the “CCAA”) [...]
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
23/06/2026
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026 ( [...]
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences
23/06/2026
NORTH PALM BEACH, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”) today announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company [...]
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
23/06/2026
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin Company intends to file the Phase 3 protocol in Q3 2026 and is actively [...]
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy [...]
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI [...]
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in [...]
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026
TORONTO, June 23, 2026 (GLOBE NEWSWIRE) -- CoreHealth Technologies Inc. today announced that Michael Peters will conclude his tenure as Chief Executive Officer at the end of June, following five years of leadership that [...]
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
23/06/2026
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company [...]

Pages